Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. (Q43726131)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. |
scientific article |
Statements
Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators (English)
Birx DL
Redfield RR
Loomis-Price LD
Aronson N
Brundage J
Davis C
Deyton L
Garner R
Gordin F
Henry D
Holloway W
Kerkering T
Luskin-Hawk R
McNeil J
Michael N
Foster Pierce P
Poretz D
Renzullo P
Ruiz N
Sitz K
Smith G
Tacket C
Thompson M
Tramont E
Yangco B